Vinicius Teixeira

In this article, we present a curated selection of over 60 molecules from September that caught our attention, along with highlights of our top picks and insights into why they stand out.

Staying on top of the latest IP disclosures in drug discovery is no small feat, so we’ve made it easier for you! Our team sifted through thousands of recently published patents to compile a curated list of about 200 significant patent documents in the drug discovery space from September 2024. Each entry is accompanied by detailed annotations to help you quickly grasp the essentials.

In this article, you'll find a curated selection of >70 molecules from August that piqued our interest, highlights of some of our favorites, and explanations of why they're worth watching.

We know keeping up with the latest developments in drug discovery can be a challenge, so we’ve simplified the process for you. We’ve reviewed thousands of newly published patent documents to bring you a curated list of over 200 key patents released in August 2024. Each entry comes with detailed commentary to help you navigate the content quickly and efficiently.

The INN Proposed List 131, released on August 11th, 2024, unveils the latest batch of drug names currently under consideration by the WHO. To streamline your review, we’ve distilled and compiled a searchable table for the small molecules that includes company identifiers, the newly proposed drug names, structural information, original patents, companies, and mechanisms of action, including structures that were previously undisclosed.

To streamline your review of the patent literature, we've distilled thousands of new documents into a searchable table featuring over 200 selected patents focused on key areas in drug discovery, all published in July 2024. Each patent includes commentary for easier navigation and understanding.

In this article, you'll find a curated selection of nearly 50 molecules from July that piqued our interest, highlights of some of our favorites, and explanations of why they're worth watching.

To help you quickly scan the patent literature, we’ve distilled down thousands of new documents into a searchable table of over 200 selected patents focused on key areas in drug discovery, all published in June 2024. This resource is enriched with detailed highlights on selected molecules targeting high-interest areas such as synthetically lethal Polθ inhibitors, SARM1 inhibitors for neurodegenerative indications, and our best guess at the identity of Gilead’s small molecule GLP-1R agonist GS-4571

To choose Molecules of the Month for June, our team reviewed hundreds of molecules from thousands of papers, press releases, conference presentations, and other sources. In this article, you'll find a curated selection of over 60 additional molecules from June that piqued our interest, along with highlights of some of our favorites and explanations of why they're worth keeping an eye on.

To help you quickly scan the patent literature, we’ve distilled down thousands of new documents into a searchable table of over 200 selected patents focused on key areas in drug discovery, all published in May 2024. This resource is enriched with detailed highlights on selected molecules targeting high-interest areas such as STING antagonists, WIZ degraders, RNA degraders, and macrocyclic amine-based OX2R modulators.

To select May’s Molecules of the Month, our team evaluated hundreds of molecules from thousands of papers, press releases, conference presentations, and other materials. Check out our curated roundup of more than 60 additional molecules below that caught our interest from May, including highlights of some of our favorites, and perspectives on why these are molecules to watch.

To select April’s Molecules of the Month, our team evaluated hundreds of molecules from thousands of papers, press releases, conference presentations, and other materials. Here we’ve curated a roundup of more than 60 additional molecules that caught our interest from April, along with highlights we found most notable.

As part of our "Molecules of the Month" and "Molecule Roundup" series of articles, which bring you the most interesting drug discovery molecules published each month, by member request, we have brought together recently highlighted molecules into a single searchable table. This tool allows you to see longer term-industry trends in therapeutic areas, target selection and chemical matter to inspire ideas for your drug discovery pipeline.

In April 2024, patent disclosures continued to highlight the swift progress in targeting key therapeutic areas. The Drug Hunter team has carefully compiled a searchable database containing over 200 patents relevant to drug discovery. This resource is enhanced with detailed annotations and highlights some of the most promising molecules and targets, such as GPR84 antagonists, brain-penetrant TYK2 inhibitors, and tricyclic urea JAK2 V617F inhibitors, among others. This compilation serves as a valuable tool for drug hunters to stay abreast of the latest trends in drug discovery.

Throughout each month, the Drug Hunter team evaluates hundreds of molecules found in thousands of papers, press releases, conference presentations, and other materials to pick contenders for Molecules of the Month. Here, we curated a roundup of nearly 70 additional molecules that caught our interest from March 2024, including highlights from some of our favorites.

In March 2024, the landscape of patent disclosures continued to reflect the rapid pace of advances against key therapeutic targets. The Drug Hunter team has curated a searchable database encompassing over 200 patents pertinent to the field of drug discovery. This resource is further enriched with insightful spotlight on some of the most promising molecules and targets, including OX2R agonists, TEAD covalent inhibitors, NaV1.8 inhibitors, and selective PI3Kγ inhibitors, among others. This round-up provides a valuable tool for drug hunters to navigate the most recent trends in drug discovery.

February 2024 saw numerous notable patent disclosures aimed at a variety of therapeutic targets across different disease areas. The Drug Hunter team has compiled a searchable table that includes more than 200 patents of relevance to the drug discovery industry. Accompanying the table are detailed notes, as well as standout features from some of our top picks, including MTA-cooperative PRMT5 inhibitors, heterobifunctional TYK2 degraders, strategies for engaging and reactivating mutant p53, and more.

The team reviews hundreds of compounds from thousands of papers, press releases, and other sources each month to select candidates for Molecules of the Month. Here we have compiled a table of >60 additional molecules that were of interest in February 2024 along with some highlights from some of our favorites below.

From WRN helicase to KRAS G12V, there were numerous hot targets of interest with patent applications published in January 2024. Here, we curated a searchable table comprising key information for more than 200 patents from January 2024 of potential interest to drug hunters, along with highlights from some of our favorites, including several degraders and molecules targeting Nrf2, KRAS G12V, MAGL, WRN, among others.

The team reviews hundreds of compounds from thousands of papers, press releases, and other sources each month to select candidates for Molecules of the Month. Here we have compiled a table of >70 additional molecules that were of interest in January 2024 along with highlights from some of our favorites, including molecules targeting SOS1, NLRP3, SMARCA2, and more.

The Drug Hunter team is piloting a new series highlighting notable disclosures in the patent literature to provide our readers a timely and scientifically flavorful synopsis of therapeutic targets being actively pursued, emerging industry breakthroughs, and fascinating chemical matter. Here we highlight 12 patents published in December 2023 that piqued our interest, and compiled a searchable table comprising key information from more than 180 additional patents of potential interest to drug hunters. If you have any suggestions on how to make this more useful, please let us know!

We’ll be reviewing 2021’s novel FDA drug approvals in a series of articles, starting with this high-level overview of the small molecule drugs approved by the FDA in 2021. You can find Part 2 on First-in-Class Small Molecules here and the 2021 Large Molecules series here . Our deep dive on Small Molecule Oncology Approvals is also live [...]